TrkB neurotrophin receptor as a drug target
Description: Neuronal plasticity is critical for learning and memory, but also for the antidepressant drug action. We recently found that essentially all antidepressants act by directly binding to TrkB, the receptor for brain-derived neurotrophic factor (BDNF) and enhancing BDNF signalling and neuroplasticity. As certain serotonin receptor agonists have been reported to produce long-lasting antidepressant effects, we will here study whether these serotonin agonists and serotonin itself might bind to TrkB and promote BDNF signalling. We will reveal the detailed structure of the binding site in TrkB and study whether the antidepressant and plasticity-promoting effects of these drugs are mediated by TrkB. We will then search for novel compounds that bind to TrkB with high affinity and selectivity. We believe that these selective high-affinity TrkB ligands could become the next generation antidepressant and plasticity enhancing drugs, producing a paradigm shift in the drug treatment of depression.
Funder: Academy of Finland
Amount: €500,000
Funding type: grant
Funder scheme: Academy Project Funding 2021
Start date: 2022-01-01
End date: 2026-08-31
Investigator: Eero Castren (lead)
Institution: University of Helsinki
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 6
Funder award ID: 347358
OpenAlex ID: G41570684
